JAMA study examines Oregon's psilocybin services model
Mental Health Weekly August 21, 2026 DOI: 10.1002/mhw.34984 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Key points | The study provides an early look at the risks and benefits of Oregon's state-regulated psilocybin program, which researchers describe as the first study of its kind in the nation. |
Abstract
Given the growing interest in psychedelic‐assisted therapies, questions remain about how such services perform outside controlled clinical trials. A new JAMA Network Open study offers an early look at the risks and benefits of Oregon's state‐regulated psilocybin program, which researchers describe as the first study of its kind in the nation.